GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Repair Ltd (ASX:TRP) » Definitions » EBIT

Tissue Repair (ASX:TRP) EBIT : A$-7.63 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tissue Repair EBIT?

Tissue Repair's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2024 was A$-3.65 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-7.63 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Tissue Repair's annualized ROC % for the quarter that ended in Dec. 2024 was -482.19%. Tissue Repair's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -1,248.59%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Tissue Repair's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -480.00%.

Tissue Repair EBIT Historical Data

The historical data trend for Tissue Repair's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tissue Repair EBIT Chart

Tissue Repair Annual Data
Trend Jun21 Jun22 Jun23 Jun24
EBIT
- -6.84 -5.74 -6.52

Tissue Repair Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EBIT Get a 7-Day Free Trial -3.38 -2.36 -2.53 -3.98 -3.65

Competitive Comparison of Tissue Repair's EBIT

For the Biotechnology subindustry, Tissue Repair's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Repair's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Repair's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tissue Repair's EV-to-EBIT falls into.


';

Tissue Repair EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-7.63 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Repair  (ASX:TRP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Tissue Repair's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-7.298 * ( 1 - 0% )/( (1.714 + 1.313)/ 2 )
=-7.298/1.5135
=-482.19 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19.39 - 1.235 - ( 16.441 - max(0, 1.337 - 19.386+16.441))
=1.714

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=16.713 - 0.967 - ( 14.433 - max(0, 1.114 - 16.705+14.433))
=1.313

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Tissue Repair's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.298/( ( (0.003 + max(-0.92, 0)) + (0.008 + max(1.158, 0)) )/ 2 )
=-7.298/( ( 0.003 + 1.166 )/ 2 )
=-7.298/0.5845
=-1,248.59 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0.215 + 0.202) - (1.235 + 0 + 0.102)
=-0.92

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.01 + 0.024 + 0.238) - (0.967 + 0 + 0.147)
=1.158

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Tissue Repair's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=-7.632/1.590
=-480.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Repair EBIT Related Terms

Thank you for viewing the detailed overview of Tissue Repair's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Tissue Repair Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tissue Repair Ltd (ASX:TRP) » Definitions » EBIT
Comparable Companies
ASX:IMC ASX:AVE ASX:RNV ASX:NYR ASX:CHM ASX:BTC ASX:ACR ASX:ANR ASX:1AI ASX:MEM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
255 Pitt Street, Level 10, Sydney, NSW, AUS, 2000
Website
https://www.tissuerepair.com.au
Tissue Repair Ltd is a clinical-stage biopharmaceutical company engaged in development of wound healing products for chronic wounds and the aftercare of cosmetic procedures, with the potential for further development of related technologies.